Near-Horizon Longevity Technologies

In the Diabetes Prevention Program, lifestyle intervention reduced diabetes progression more than metformin. The article frames the key shift as moving from disease-by-disease treatment to targeting aging at its core. Metformin is described as influencing AMPK and improving insulin sensitivity, which could support longevity pathways. Future interventions may address aging processes that increase vulnerability to many diseases at once. The article warns that GLP-1-associated weight loss may include substantial muscle loss. The article raises concerns about metformin as a general anti-aging drug. Stopping GLP-1 therapy is associated in the source with substantial weight regain for the average person. Gene editing, gene therapy, organ regeneration, and longevity drugs are expected to become available or more mature in the near horizon. GLP-1 agonists are presented as potentially valuable for severe obesity rather than rejected outright.